Deep Learning Based Methods for Breast Cancer Diagnosis: A Systematic Review and Future Direction

Performance of Progressive Generations of GPT on an Exam Designed for Certifying Physicians as Certified Clinical Densitometrists

BACKGROUND

Artificial intelligence (AI) large language models (LLMs) such as ChatGPT have demonstrated the ability to pass standardized exams. These models are not trained for a specific task, but instead trained to predict sequences of text from large corpora of documents sourced from the internet. It has been shown that even models trained on this general task can pass exams in a variety of domain-specific fields, including the United States Medical Licensing Examination. We asked if large language models would perform as well on a much narrower subdomain tests designed for medical specialists. Furthermore, we wanted to better understand how progressive generations of GPT (generative pre-trained transformer) models may be evolving in the completeness and sophistication of their responses even while generational training remains general. In this study, we evaluated the performance of two versions of GPT (GPT 3 and 4) on their ability to pass the certification exam given to physicians to work as osteoporosis specialists and become a certified clinical densitometrists. The CCD exam has a possible score range of 150 to 400. To pass, you need a score of 300.

METHODS

A 100-question multiple-choice practice exam was obtained from a 3rd party exam preparation website that mimics the accredited certification tests given by the ISCD (International Society for Clinical Densitometry). The exam was administered to two versions of GPT, the free version (GPT Playground) and ChatGPT+, which are based on GPT-3 and GPT-4, respectively (OpenAI, San Francisco, CA). The systems were prompted with the exam questions verbatim. If the response was purely textual and did not specify which of the multiple-choice answers to select, the authors matched the text to the closest answer. Each exam was graded and an estimated ISCD score was provided from the exam website. In addition, each response was evaluated by a rheumatologist CCD and ranked for accuracy using a 5-level scale. The two GPT versions were compared in terms of response accuracy and length.

RESULTS

The average response length was 11.6 ±19 words for GPT-3 and 50.0±43.6 words for GPT-4. GPT-3 answered 62 questions correctly resulting in a failing ISCD score of 289. However, GPT-4 answered 82 questions correctly with a passing score of 342. GPT-3 scored highest on the "Overview of Low Bone Mass and Osteoporosis" category (72 % correct) while GPT-4 scored well above 80 % accuracy on all categories except "Imaging Technology in Bone Health" (65 % correct). Regarding subjective accuracy, GPT-3 answered 23 questions with nonsensical or totally wrong responses while GPT-4 had no responses in that category.

CONCLUSION

If this had been an actual certification exam, GPT-4 would now have a CCD suffix to its name even after being trained using general internet knowledge. Clearly, more goes into physician training than can be captured in this exam. However, GPT algorithms may prove to be valuable physician aids in the diagnoses and monitoring of osteoporosis and other diseases.

Advancing Breast Cancer Research Through Collaborative Computing: Harnessing Google Colab for Innovation

This investigation explores the potential efficacy of machine learning algorithms (MLAs), particularly convolutional neural networks (CNNs), in distinguishing between benign and malignant breast cancer tissue through the analysis of 1000 breast cancer images gathered from Kaggle.com, a domain of publicly accessible data. The dataset was meticulously partitioned into training, validation, and testing sets to facilitate model development and evaluation. Our results reveal promising outcomes, with the developed model achieving notable precision (92%), recall (92%), accuracy (92%), sensitivity (89%), specificity (96%), an F1 score of 0.92, and an area under the curve (AUC) of 0.944. These metrics underscore the model's ability to accurately identify malignant breast cancer images. Because of limitations such as sample size and potential variations in image quality, further research, data collection, and integration of theoretical models in a real-world clinical setting are needed to expand the reliability and generalizability of these MLAs. Nonetheless, this study serves to highlight the potential use of artificial intelligence models as supporting tools for physicians to utilize in breast cancer detection.

Refining breast cancer biomarker discovery and drug targeting through an advanced data-driven approach

Breast cancer remains a major public health challenge worldwide. The identification of accurate biomarkers is critical for the early detection and effective treatment of breast cancer. This study utilizes an integrative machine learning approach to analyze breast cancer gene expression data for superior biomarker and drug target discovery. Gene expression datasets, obtained from the GEO database, were merged post-preprocessing. From the merged dataset, differential expression analysis between breast cancer and normal samples revealed 164 differentially expressed genes. Meanwhile, a separate gene expression dataset revealed 350 differentially expressed genes. Additionally, the BGWO_SA_Ens algorithm, integrating binary grey wolf optimization and simulated annealing with an ensemble classifier, was employed on gene expression datasets to identify predictive genes including TOP2A, AKR1C3, EZH2, MMP1, EDNRB, S100B, and SPP1. From over 10,000 genes, BGWO_SA_Ens identified 1404 in the merged dataset (F1 score: 0.981, PR-AUC: 0.998, ROC-AUC: 0.995) and 1710 in the GSE45827 dataset (F1 score: 0.965, PR-AUC: 0.986, ROC-AUC: 0.972). The intersection of DEGs and BGWO_SA_Ens selected genes revealed 35 superior genes that were consistently significant across methods. Enrichment analyses uncovered the involvement of these superior genes in key pathways such as AMPK, Adipocytokine, and PPAR signaling. Protein-protein interaction network analysis highlighted subnetworks and central nodes. Finally, a drug-gene interaction investigation revealed connections between superior genes and anticancer drugs. Collectively, the machine learning workflow identified a robust gene signature for breast cancer, illuminated their biological roles, interactions and therapeutic associations, and underscored the potential of computational approaches in biomarker discovery and precision oncology.

The Application of Artificial Intelligence to Cancer Research: A Comprehensive Guide

Advancements in AI have notably changed cancer research, improving patient care by enhancing detection, survival prediction, and treatment efficacy. This review covers the role of Machine Learning, Soft Computing, and Deep Learning in oncology, explaining key concepts and algorithms (like SVM, Naïve Bayes, and CNN) in a clear, accessible manner. It aims to make AI advancements understandable to a broad audience, focusing on their application in diagnosing, classifying, and predicting various cancer types, thereby underlining AI's potential to better patient outcomes. Moreover, we present a tabular summary of the most significant advances from the literature, offering a time-saving resource for readers to grasp each study's main contributions. The remarkable benefits of AI-powered algorithms in cancer care underscore their potential for advancing cancer research and clinical practice. This review is a valuable resource for researchers and clinicians interested in the transformative implications of AI in cancer care.

Artificial intelligence in breast imaging: potentials and challenges

Breast cancer, which is the most common type of malignant tumor among humans, is a leading cause of death in females. Standard treatment strategies, including neoadjuvant chemotherapy, surgery, postoperative chemotherapy, targeted therapy, endocrine therapy, and radiotherapy, are tailored for individual patients. Such personalized therapies have tremendously reduced the threat of breast cancer in females. Furthermore, early imaging screening plays an important role in reducing the treatment cycle and improving breast cancer prognosis. The recent innovative revolution in artificial intelligence (AI) has aided radiologists in the early and accurate diagnosis of breast cancer. In this review, we introduce the necessity of incorporating AI into breast imaging and the applications of AI in mammography, ultrasonography, magnetic resonance imaging, and positron emission tomography/computed tomography based on published articles since 1994. Moreover, the challenges of AI in breast imaging are discussed.

Training and validation of a novel non-invasive imaging system for ruling out malignancy in canine subcutaneous and cutaneous masses using machine learning in 664 masses

Objective

To train and validate the use of a novel artificial intelligence-based thermal imaging system as a screening tool to rule out malignancy in cutaneous and subcutaneous masses in dogs.

Animals

Training study: 147 client-owned dogs with 233 masses. Validation Study: 299 client-owned dogs with 525 masses. Cytology was non-diagnostic in 94 masses, resulting in 431 masses from 248 dogs with diagnostic samples.

Procedures

The prospective studies were conducted between June 2020 and July 2022. During the scan, each mass and its adjacent healthy tissue was heated by a high-power Light-Emitting Diode. The tissue temperature was recorded by the device and consequently analyzed using a supervised machine learning algorithm to determine whether the mass required further investigation. The first study was performed to collect data to train the algorithm. The second study validated the algorithm, as the real-time device predictions were compared to the cytology and/or biopsy results.

Results

The results for the validation study were that the device correctly classified 45 out of 53 malignant masses and 253 out of 378 benign masses (sensitivity = 85% and specificity = 67%). The negative predictive value of the system (i.e., percent of benign masses identified as benign) was 97%.

Clinical relevance

The results demonstrate that this novel system could be used as a decision-support tool at the point of care, enabling clinicians to differentiate between benign lesions and those requiring further diagnostics.

MSRNet: Multiclass Skin Lesion Recognition Using Additional Residual Block Based Fine-Tuned Deep Models Information Fusion and Best Feature Selection

Cancer is one of the leading significant causes of illness and chronic disease worldwide. Skin cancer, particularly melanoma, is becoming a severe health problem due to its rising prevalence. The considerable death rate linked with melanoma requires early detection to receive immediate and successful treatment. Lesion detection and classification are more challenging due to many forms of artifacts such as hairs, noise, and irregularity of lesion shape, color, irrelevant features, and textures. In this work, we proposed a deep-learning architecture for classifying multiclass skin cancer and melanoma detection. The proposed architecture consists of four core steps: image preprocessing, feature extraction and fusion, feature selection, and classification. A novel contrast enhancement technique is proposed based on the image luminance information. After that, two pre-trained deep models, DarkNet-53 and DensNet-201, are modified in terms of a residual block at the end and trained through transfer learning. In the learning process, the Genetic algorithm is applied to select hyperparameters. The resultant features are fused using a two-step approach named serial-harmonic mean. This step increases the accuracy of the correct classification, but some irrelevant information is also observed. Therefore, an algorithm is developed to select the best features called marine predator optimization (MPA) controlled Reyni Entropy. The selected features are finally classified using machine learning classifiers for the final classification. Two datasets, ISIC2018 and ISIC2019, have been selected for the experimental process. On these datasets, the obtained maximum accuracy of 85.4% and 98.80%, respectively. To prove the effectiveness of the proposed methods, a detailed comparison is conducted with several recent techniques and shows the proposed framework outperforms.

A Deep Learning Model Based on Capsule Networks for COVID Diagnostics through X-ray Images

X-ray diagnostics are widely used to detect various diseases, such as bone fracture, pneumonia, or intracranial hemorrhage. This method is simple and accessible in most hospitals, but requires an expert who is sometimes unavailable. Today, some diagnoses are made with the help of deep learning algorithms based on Convolutional Neural Networks (CNN), but these algorithms show limitations. Recently, Capsule Networks (CapsNet) have been proposed to overcome these problems. In our work, CapsNet is used to detect whether a chest X-ray image has disease (COVID or pneumonia) or is healthy. An improved model called DRCaps is proposed, which combines the advantage of CapsNet and the dilation rate (dr) parameter to manage images with 226 × 226 resolution. We performed experiments with 16,669 chest images, in which our model achieved an accuracy of 90%. Furthermore, the model size is 11M with a reconstruction stage, which helps to avoid overfitting. Experiments show how the reconstruction stage works and how we can avoid the max-pooling operation for networks with a stride and dilation rate to downsampling the convolution layers. In this paper, DRCaps is superior to other comparable models in terms of accuracy, parameters, and image size handling. The main idea is to keep the model as simple as possible without using data augmentation or a complex preprocessing stage.

Deep learning and ultrasound feature fusion model predicts the malignancy of complex cystic and solid breast nodules with color Doppler images

This study aimed to evaluate the performance of traditional-deep learning combination model based on Doppler ultrasound for diagnosing malignant complex cystic and solid breast nodules. A conventional statistical prediction model based on the ultrasound features and basic clinical information was established. A deep learning prediction model was used to train the training group images and derive the deep learning prediction model. The two models were validated, and their accuracy rates were compared using the data and images of the test group, respectively. A logistic regression method was used to combine the two models to derive a combination diagnostic model and validate it in the test group. The diagnostic performance of each model was represented by the receiver operating characteristic curve and the area under the curve. In the test cohort, the diagnostic efficacy of the deep learning model was better than traditional statistical model, and the combined diagnostic model was better and outperformed the other two models (combination model vs traditional statistical model: AUC: 0.95 > 0.70, P = 0.001; combination model vs deep learning model: AUC: 0.95 > 0.87, P = 0.04). A combination model based on deep learning and ultrasound features has good diagnostic value.

Early Screening of Colorectal Precancerous Lesions Based on Combined Measurement of Multiple Serum Tumor Markers Using Artificial Neural Network Analysis

Many patients with colorectal cancer (CRC) are diagnosed in the advanced stage, resulting in delayed treatment and reduced survival time. It is urgent to develop accurate early screening methods for CRC. The purpose of this study is to develop an artificial intelligence (AI)-based artificial neural network (ANN) model using multiple protein tumor markers to assist in the early diagnosis of CRC and precancerous lesions. In this retrospective analysis, 148 cases with CRC and precancerous diseases were included. The concentrations of multiple protein tumor markers (CEA, CA19-9, CA 125, CYFRA 21-1, CA 72-4, CA 242) were measured by electrochemical luminescence immunoassays. By combining these markers with an ANN algorithm, a diagnosis model (CA6) was developed to distinguish between normal healthy and abnormal subjects, with an AUC of 0.97. The prediction score derived from the CA6 model also performed well in assisting in the diagnosis of precancerous lesions and early CRC (with AUCs of 0.97 and 0.93 and cut-off values of 0.39 and 0.34, respectively), which was better than that of individual protein tumor indicators. The CA6 model established by ANN provides a new and effective method for laboratory auxiliary diagnosis, which might be utilized for early colorectal lesion screening by incorporating more tumor markers with larger sample size.

Identification of Novel Diagnostic and Prognostic Gene Signature Biomarkers for Breast Cancer Using Artificial Intelligence and Machine Learning Assisted Transcriptomics Analysis

BACKGROUND

Breast cancer (BC) is one of the most common female cancers. Clinical and histopathological information is collectively used for diagnosis, but is often not precise. We applied machine learning (ML) methods to identify the valuable gene signature model based on differentially expressed genes (DEGs) for BC diagnosis and prognosis.

METHODS

A cohort of 701 samples from 11 GEO BC microarray datasets was used for the identification of significant DEGs. Seven ML methods, including RFECV-LR, RFECV-SVM, LR-L1, SVC-L1, RF, and Extra-Trees were applied for gene reduction and the construction of a diagnostic model for cancer classification. Kaplan-Meier survival analysis was performed for prognostic signature construction. The potential biomarkers were confirmed via qRT-PCR and validated by another set of ML methods including GBDT, XGBoost, AdaBoost, KNN, and MLP.

RESULTS

We identified 355 DEGs and predicted BC-associated pathways, including kinetochore metaphase signaling, PTEN, senescence, and phagosome-formation pathways. A hub of 28 DEGs and a novel diagnostic nine-gene signature (COL10A, S100P, ADAMTS5, WISP1, COMP, CXCL10, LYVE1, COL11A1, and INHBA) were identified using stringent filter conditions. Similarly, a novel prognostic model consisting of eight-gene signatures (CCNE2, NUSAP1, TPX2, S100P, ITM2A, LIFR, TNXA, and ZBTB16) was also identified using disease-free survival and overall survival analysis. Gene signatures were validated by another set of ML methods. Finally, qRT-PCR results confirmed the expression of the identified gene signatures in BC.

CONCLUSION

The ML approach helped construct novel diagnostic and prognostic models based on the expression profiling of BC. The identified nine-gene signature and eight-gene signatures showed excellent potential in BC diagnosis and prognosis, respectively.